Successful management of hypoparathyroidism with PTH (1-34) or teriparatide
PDF (Español (España))

Keywords

Hypoparathyroidism
Teriparatide
Calcium Metabolism Disorders
Parathyroid Hormone

How to Cite

Severiche Bueno, D. F. ., Serpa Serpa, C. M. ., Gutiérrez-Morales, C. V. ., & Rincón-Sierra, O. . (2021). Successful management of hypoparathyroidism with PTH (1-34) or teriparatide. Revista Endocrino, 8(1). https://doi.org/10.53853/encr.8.1.697

Abstract

Hypoparathyroidism is a rare disease that by 2013 was the only endocrine disease for which management with the missing hormone was not approved.  In 2015 the use of PTH (1-84) was approved by the FDA, however this therapy is not available in all countries and its use implies high costs for health systems. Therefore, the use of PTH (1-34) can be considered as an alternative, considering that the studies with this molecule are prior to the studies of PTH (1-84) with good results in the patients evaluated. It is important to highlight that most of the patients in the clinical studies of both molecules were patients with postsurgical hypoparathyroidism, therefore their use in patients with hypoparathyroidism not due to surgical etiology is not well established.

https://doi.org/10.53853/encr.8.1.697
PDF (Español (España))

References

Rachel IG, Michael TC. Hypoparathyroidism. N Engl J Med. 2019; 380(18): p. 1738-1747.

https://doi.org/10.1056/NEJMcp1800213

Michael M, John PB, Rajesh VT, Fadil MH, Bart LC, Lars R, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017; 3(17055).

https://doi.org/10.1038/nrdp.2017.56

Bart LC. Epidemiology and Complications of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018; 47(4): p. 771-782.

https://doi.org/10.1016/j.ecl.2018.07.004

Jens B, Lars R, Claudio M, Dolores MS, Antonio SS, Wim VB, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015; 173(2): p. G1-G20.

https://doi.org/10.1530/EJE-15-0628

Gaia T, John PB. New Directions in Treatment of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018; 47(4): p. 901-915.

https://doi.org/10.1016/j.ecl.2018.07.013

Karen KW, Jack AY, Gordon BC. Synthetic human parathyroid hormone 1-34 vs. calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996; 276: p. 631-6.

https://doi.org/10.1001/jama.276.8.631

Cusano NE, Rubin MR, Irani D, Sliney J, Bilezikian JP. Use of parathyroid hormone in hypoparathyroidism. 2013; 36(11): p. 1121-1127.

https://doi.org/10.1007/BF03346763

Karen KW, Chia WK, James CR, Karen D, Meg K, Donna P, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003; 88: p. 4214-20.

Rachel IG, Jaime S, Brahim DDS, Panagiota A, Nisan B, Marilyn H, et al. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res. 2012; 27: p. 1811-20.

https://doi.org/10.1002/jbmr.1627

Santonati A, Palermo A, Maddaloni E, et al. PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2015; 100(9): p. 3590-7.

https://doi.org/10.1210/jc.2015-1855

Palermo A, Santonati A, Tabacco G, et al. PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2018; 103(1): p. 271-80.

https://doi.org/10.1210/jc.2017-01555

Rubin MR, Sliney J, McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010; p. 1927-34.

https://doi.org/10.1007/s00198-009-1149-x

Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a doubleblind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013; 1(4): p. 275-83.

https://doi.org/10.1016/S2213-8587(13)70106-2

Lakatos P, Bajnok L, Lagast H, et al. An open-label extension study of parathyroid hormone RHPTH(1-84) in adults with hypoparathyroidism. Endocr Pract. 2016;: p. 523-32.

https://doi.org/10.4158/EP15936.OR

Cusano NE, Rubin MRMDJea. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013; 98(1): p. 137-44.

https://doi.org/10.1210/jc.2012-2984

Rubin MR, Cusano NE, Fan WW, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016; 101(7): p. 2742-50.

https://doi.org/10.1210/jc.2015-4135

Cardona E, Builes-Barrera A, Roman-Gonzales A. Trtamiento del hipoparartiorisimo con hormona paratiroidea. Revista Colombiana de Endocrinología. 2019; 6(1): p. 35-41.

https://doi.org/10.53853/encr.6.1.466

Arenas H, Hoyos JA, Alzate JA. Uso de paratohormona 1-34 en pacientes con hipoparatiroidismo secundario refractario. Reporte de 2 casos en la ciudad de Pereira. Rev. Méd. Risaralda. 2016; 22(2): p. 02-104.

https://doi.org/10.22517/25395203.9109

Restrepo-Valencia C, Mnajarres-Iglesias G. Fracaso de la hormona sintética paratiroidea (teriparatide) en el tratamiento del hipoparatiroidismo posquirurgico. Médicas UIS. 2011; 24(1): p. 97-103.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.